To assess the impact of the Novartis Cardio Metabolic Program—an education, awareness, and health management initiative—on hypertension, hyperlipidemia, diabetes mellitus, and obesity within the Novartis employee population.
A prospective, 6-month pre-/post assessment to determine improvement in blood pressure (BP) control and risk factors after implementation of Novartis Cardio Metabolic.
A total of 238 subjects with cardiovascular risk factors participated. In the hypertension cohort, overall BP control improved from 38% at baseline to 79% at follow-up (P < 0.0001). In the hyperlipidemia cohort, low-density lipoprotein cholesterol control improved significantly between baseline and study end (22% to 34%, P = 0.0004). In the diabetes mellitus cohort, the rate of glycosylated hemoglobin control increased from 83.7% to 86.2% (P = 0.69). There was a significant decrease in body mass index at follow-up (P < 0.0001).
Novartis Cardio Metabolic educational and health interventions helped to improve health awareness among Novartis employees.
From Novartis Pharmaceuticals (Drs Mauceri and Hanson, Ms Bienkowski, and Mr Doyle), East Hanover, NJ; and Xcenda (Dr Jackson and Ms Bramer), Palm Harbor, Fla.
Address correspondence to: Susan Bramer, MS, Xcenda, LLC, 4114 Woodlands Parkway, Suite 500, Palm Harbor, FL 34685 (email@example.com)
Funding for this work was provided by Novartis Pharmaceuticals.